Recruiting

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(25 sites)

United States

Research Site, Jacksonville, Florida

Research Site, Rochester, Minnesota

Research Site, New York, New York

China

Research Site, Beijing

Research Site, Shandong

France

Research Site, Toulouse

Research Site, Villejuif

Japan

Research Site, Chūōku

Research Site, Kashiwa

Research Site, Kōtoku

Netherlands

Research Site, Amsterdam

Research Site, Groningen

Research Site, Rotterdam

South Korea

Research Site, Seoul

Taiwan

Research Site, Kaohsiung City

Research Site, Tainan

Research Site, Taoyuan District

United Kingdom

Research Site, Dundee

Research Site, London

Research Site, Metropolitan Borough of Wirral

Research Site, Oxford